Reducing Systemic Inflammation in People on Antiretroviral Therapy

This randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between participants who receive fostemsavir in addition to their existing treatment and those who continue with standard care alone.

NCT Number	NCT07030920
Lead Sponsor	Centre hospitalier de l'Université de Montréal (CHUM) Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, Clinique du Quartier Latin, BC Women's Hospital & Health Centre
Conditions	Human Immunodeficiency Virus (HIV), Cardiovascular Risk Factor
Enrollment	150 participants
Start Date	2025-09-30
Primary Completion	2028-10 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2025-11-19